Anixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC Wainwright

Anixa Biosciences (NASDAQ:ANIXGet Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 129.13% from the company’s previous close.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

View Our Latest Analysis on Anixa Biosciences

Anixa Biosciences Stock Performance

NASDAQ:ANIX traded down $0.09 during trading hours on Tuesday, reaching $3.06. The company’s stock had a trading volume of 59,132 shares, compared to its average volume of 121,007. The firm has a market capitalization of $98.37 million, a price-to-earnings ratio of -7.83 and a beta of 0.93. The firm has a 50-day simple moving average of $2.70 and a 200-day simple moving average of $3.05. Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last announced its quarterly earnings data on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities analysts anticipate that Anixa Biosciences will post -0.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In related news, CEO Amit Kumar purchased 43,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the acquisition, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 75,289 shares of company stock worth $177,021. 22.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

Large investors have recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in Anixa Biosciences in the fourth quarter worth about $26,000. Virtu Financial LLC bought a new position in shares of Anixa Biosciences in the 3rd quarter worth approximately $34,000. Renaissance Technologies LLC boosted its position in shares of Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock valued at $34,000 after purchasing an additional 3,900 shares in the last quarter. Prosperity Wealth Management Inc. purchased a new stake in Anixa Biosciences in the fourth quarter worth $54,000. Finally, Jane Street Group LLC bought a new position in Anixa Biosciences in the fourth quarter worth $67,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

See Also

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.